IBDEI3IP ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,1817,0)
 ;;=NEW PATIENT^2^165
 ;;^UTILITY(U,$J,358.4,1818,0)
 ;;=ESTABLISHED PATIENT^1^165
 ;;^UTILITY(U,$J,358.4,1819,0)
 ;;=CONSULTATIONS^3^165
 ;;^UTILITY(U,$J,358.4,1820,0)
 ;;=PREGNANCY COMPLICATIONS^9^166
 ;;^UTILITY(U,$J,358.4,1821,0)
 ;;=PREGNANCY-HYPERTENSION^12^166
 ;;^UTILITY(U,$J,358.4,1822,0)
 ;;=PREGNANCY-VOMITING^15^166
 ;;^UTILITY(U,$J,358.4,1823,0)
 ;;=LATE PREGNANCY^6^166
 ;;^UTILITY(U,$J,358.4,1824,0)
 ;;=PREGNANCY-OTH COMPLICATIONS^13^166
 ;;^UTILITY(U,$J,358.4,1825,0)
 ;;=PREGNANCY CONDITIONS^10^166
 ;;^UTILITY(U,$J,358.4,1826,0)
 ;;=MULTIPLE GESTATIONS^8^166
 ;;^UTILITY(U,$J,358.4,1827,0)
 ;;=PREGNANCY-FETAL ABNORMALITY^11^166
 ;;^UTILITY(U,$J,358.4,1828,0)
 ;;=AMNIO/MEMBRANE PROBLEMS^1^166
 ;;^UTILITY(U,$J,358.4,1829,0)
 ;;=MAJOR PUERPERAL INFECTIONS^7^166
 ;;^UTILITY(U,$J,358.4,1830,0)
 ;;=VENOUS COMPLICATIONS^18^166
 ;;^UTILITY(U,$J,358.4,1831,0)
 ;;=PREGNANCY-PYREXIA^14^166
 ;;^UTILITY(U,$J,358.4,1832,0)
 ;;=PUERPERIUM COMPLICATIONS^17^166
 ;;^UTILITY(U,$J,358.4,1833,0)
 ;;=INFECTIONS BREAST/NIPPLE^5^166
 ;;^UTILITY(U,$J,358.4,1834,0)
 ;;=PREGNANCY-Z CODES^16^166
 ;;^UTILITY(U,$J,358.4,1835,0)
 ;;=GYNECOLOGICAL/BREAST^4^166
 ;;^UTILITY(U,$J,358.4,1836,0)
 ;;=GENITOURINARY & RENAL^3^166
 ;;^UTILITY(U,$J,358.4,1837,0)
 ;;=GASTROINTESTINAL^2^166
 ;;^UTILITY(U,$J,358.4,1838,0)
 ;;=SPECIAL SERVICES^9^167
 ;;^UTILITY(U,$J,358.4,1839,0)
 ;;=CHEMO NURSE PROCEDURES^2^167
 ;;^UTILITY(U,$J,358.4,1840,0)
 ;;=INFUSION DRUGS^6^167
 ;;^UTILITY(U,$J,358.4,1841,0)
 ;;=BLOOD PRODUCTS^1^167
 ;;^UTILITY(U,$J,358.4,1842,0)
 ;;=DIAGNOSTIC PROCEDURES^3^167
 ;;^UTILITY(U,$J,358.4,1843,0)
 ;;=OTHER DRUGS^7^167
 ;;^UTILITY(U,$J,358.4,1844,0)
 ;;=IMMUNIZATION ADMINISTRATION^4^167
 ;;^UTILITY(U,$J,358.4,1845,0)
 ;;=IMMUNIZATIONS^5^167
 ;;^UTILITY(U,$J,358.4,1846,0)
 ;;=PROLONGED SERVICES^8^167
 ;;^UTILITY(U,$J,358.4,1847,0)
 ;;=NEW PATIENT^2^168
 ;;^UTILITY(U,$J,358.4,1848,0)
 ;;=ESTABLISHED PATIENT^1^168
 ;;^UTILITY(U,$J,358.4,1849,0)
 ;;=CONSULTATIONS^3^168
 ;;^UTILITY(U,$J,358.4,1850,0)
 ;;=ANEMIA^1^169
 ;;^UTILITY(U,$J,358.4,1851,0)
 ;;=ARTIFICIAL OPENING STATUS^2^169
 ;;^UTILITY(U,$J,358.4,1852,0)
 ;;=BREASTS and GYN NEOPLASMS^3^169
 ;;^UTILITY(U,$J,358.4,1853,0)
 ;;=COAGULATION DISORDERS^4^169
 ;;^UTILITY(U,$J,358.4,1854,0)
 ;;=COUNSELING AND SCREENING^5^169
 ;;^UTILITY(U,$J,358.4,1855,0)
 ;;=GENITOURINARY NEOPLASMS^6^169
 ;;^UTILITY(U,$J,358.4,1856,0)
 ;;=GI CANCER^7^169
 ;;^UTILITY(U,$J,358.4,1857,0)
 ;;=HEAD NECK AND LUNGS NEOPLASMS^8^169
 ;;^UTILITY(U,$J,358.4,1858,0)
 ;;=HEMOGLOBINOPATHIES^9^169
 ;;^UTILITY(U,$J,358.4,1859,0)
 ;;=LYMPHOID NEOPLASMS^10^169
 ;;^UTILITY(U,$J,358.4,1860,0)
 ;;=METASTATIC SITES^11^169
 ;;^UTILITY(U,$J,358.4,1861,0)
 ;;=MALIGNANT NEOPLASMS OF OTHER SITES^12^169
 ;;^UTILITY(U,$J,358.4,1862,0)
 ;;=MYELOID NEOPLASMS AND DISORDERS^13^169
 ;;^UTILITY(U,$J,358.4,1863,0)
 ;;=NEOPLASM OF UNCERTAIN BEHAVIOR^14^169
 ;;^UTILITY(U,$J,358.4,1864,0)
 ;;=NEOPLASM OF UNSPECIFIED NATURE^15^169
 ;;^UTILITY(U,$J,358.4,1865,0)
 ;;=PERSONAL HISTORY^16^169
 ;;^UTILITY(U,$J,358.4,1866,0)
 ;;=INJECTION/ASPIRATION^3^170
 ;;^UTILITY(U,$J,358.4,1867,0)
 ;;=FRACTURE DISLOCATION^2^170
 ;;^UTILITY(U,$J,358.4,1868,0)
 ;;=APPLICATION CASTS/STRAPPING^1^170
 ;;^UTILITY(U,$J,358.4,1869,0)
 ;;=OTHER/REMOVAL/REVISION^4^170
 ;;^UTILITY(U,$J,358.4,1870,0)
 ;;=SUPPLIES/SOFT GOODS^7^170
 ;;^UTILITY(U,$J,358.4,1871,0)
 ;;=SUPPLIES/DRUGS^6^170
 ;;^UTILITY(U,$J,358.4,1872,0)
 ;;=REPAIR/CLOSURE-SIMPLE^5^170
 ;;^UTILITY(U,$J,358.4,1873,0)
 ;;=NEW PATIENT^2^171
 ;;^UTILITY(U,$J,358.4,1874,0)
 ;;=ESTABLISHED PATIENT^1^171
 
--- Routine Detail   --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI3IP   3971     printed  Sep 23, 2025@20:25:36                                                                                                                                                                                                    Page 2
IBDEI3IP  ; ; 19-NOV-2015
 +1       ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 +2        if 'DIFQR(358.4)
               QUIT 
           FOR I=1:2
               SET X=$TEXT(Q+I)
               if X=""
                   QUIT 
               SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
               SET X=$EXTRACT(X,4,999)
               if $ASCII(Y)=126
                   SET I=I+1
                   SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,99)
               if $ASCII(Y)=61
                   SET Y=$EXTRACT(Y,2,999)
               XECUTE NO
              IF '$TEST
                   SET @X=Y
Q          QUIT 
 +1       ;;^UTILITY(U,$J,358.4,1817,0)
 +2       ;;=NEW PATIENT^2^165
 +3       ;;^UTILITY(U,$J,358.4,1818,0)
 +4       ;;=ESTABLISHED PATIENT^1^165
 +5       ;;^UTILITY(U,$J,358.4,1819,0)
 +6       ;;=CONSULTATIONS^3^165
 +7       ;;^UTILITY(U,$J,358.4,1820,0)
 +8       ;;=PREGNANCY COMPLICATIONS^9^166
 +9       ;;^UTILITY(U,$J,358.4,1821,0)
 +10      ;;=PREGNANCY-HYPERTENSION^12^166
 +11      ;;^UTILITY(U,$J,358.4,1822,0)
 +12      ;;=PREGNANCY-VOMITING^15^166
 +13      ;;^UTILITY(U,$J,358.4,1823,0)
 +14      ;;=LATE PREGNANCY^6^166
 +15      ;;^UTILITY(U,$J,358.4,1824,0)
 +16      ;;=PREGNANCY-OTH COMPLICATIONS^13^166
 +17      ;;^UTILITY(U,$J,358.4,1825,0)
 +18      ;;=PREGNANCY CONDITIONS^10^166
 +19      ;;^UTILITY(U,$J,358.4,1826,0)
 +20      ;;=MULTIPLE GESTATIONS^8^166
 +21      ;;^UTILITY(U,$J,358.4,1827,0)
 +22      ;;=PREGNANCY-FETAL ABNORMALITY^11^166
 +23      ;;^UTILITY(U,$J,358.4,1828,0)
 +24      ;;=AMNIO/MEMBRANE PROBLEMS^1^166
 +25      ;;^UTILITY(U,$J,358.4,1829,0)
 +26      ;;=MAJOR PUERPERAL INFECTIONS^7^166
 +27      ;;^UTILITY(U,$J,358.4,1830,0)
 +28      ;;=VENOUS COMPLICATIONS^18^166
 +29      ;;^UTILITY(U,$J,358.4,1831,0)
 +30      ;;=PREGNANCY-PYREXIA^14^166
 +31      ;;^UTILITY(U,$J,358.4,1832,0)
 +32      ;;=PUERPERIUM COMPLICATIONS^17^166
 +33      ;;^UTILITY(U,$J,358.4,1833,0)
 +34      ;;=INFECTIONS BREAST/NIPPLE^5^166
 +35      ;;^UTILITY(U,$J,358.4,1834,0)
 +36      ;;=PREGNANCY-Z CODES^16^166
 +37      ;;^UTILITY(U,$J,358.4,1835,0)
 +38      ;;=GYNECOLOGICAL/BREAST^4^166
 +39      ;;^UTILITY(U,$J,358.4,1836,0)
 +40      ;;=GENITOURINARY & RENAL^3^166
 +41      ;;^UTILITY(U,$J,358.4,1837,0)
 +42      ;;=GASTROINTESTINAL^2^166
 +43      ;;^UTILITY(U,$J,358.4,1838,0)
 +44      ;;=SPECIAL SERVICES^9^167
 +45      ;;^UTILITY(U,$J,358.4,1839,0)
 +46      ;;=CHEMO NURSE PROCEDURES^2^167
 +47      ;;^UTILITY(U,$J,358.4,1840,0)
 +48      ;;=INFUSION DRUGS^6^167
 +49      ;;^UTILITY(U,$J,358.4,1841,0)
 +50      ;;=BLOOD PRODUCTS^1^167
 +51      ;;^UTILITY(U,$J,358.4,1842,0)
 +52      ;;=DIAGNOSTIC PROCEDURES^3^167
 +53      ;;^UTILITY(U,$J,358.4,1843,0)
 +54      ;;=OTHER DRUGS^7^167
 +55      ;;^UTILITY(U,$J,358.4,1844,0)
 +56      ;;=IMMUNIZATION ADMINISTRATION^4^167
 +57      ;;^UTILITY(U,$J,358.4,1845,0)
 +58      ;;=IMMUNIZATIONS^5^167
 +59      ;;^UTILITY(U,$J,358.4,1846,0)
 +60      ;;=PROLONGED SERVICES^8^167
 +61      ;;^UTILITY(U,$J,358.4,1847,0)
 +62      ;;=NEW PATIENT^2^168
 +63      ;;^UTILITY(U,$J,358.4,1848,0)
 +64      ;;=ESTABLISHED PATIENT^1^168
 +65      ;;^UTILITY(U,$J,358.4,1849,0)
 +66      ;;=CONSULTATIONS^3^168
 +67      ;;^UTILITY(U,$J,358.4,1850,0)
 +68      ;;=ANEMIA^1^169
 +69      ;;^UTILITY(U,$J,358.4,1851,0)
 +70      ;;=ARTIFICIAL OPENING STATUS^2^169
 +71      ;;^UTILITY(U,$J,358.4,1852,0)
 +72      ;;=BREASTS and GYN NEOPLASMS^3^169
 +73      ;;^UTILITY(U,$J,358.4,1853,0)
 +74      ;;=COAGULATION DISORDERS^4^169
 +75      ;;^UTILITY(U,$J,358.4,1854,0)
 +76      ;;=COUNSELING AND SCREENING^5^169
 +77      ;;^UTILITY(U,$J,358.4,1855,0)
 +78      ;;=GENITOURINARY NEOPLASMS^6^169
 +79      ;;^UTILITY(U,$J,358.4,1856,0)
 +80      ;;=GI CANCER^7^169
 +81      ;;^UTILITY(U,$J,358.4,1857,0)
 +82      ;;=HEAD NECK AND LUNGS NEOPLASMS^8^169
 +83      ;;^UTILITY(U,$J,358.4,1858,0)
 +84      ;;=HEMOGLOBINOPATHIES^9^169
 +85      ;;^UTILITY(U,$J,358.4,1859,0)
 +86      ;;=LYMPHOID NEOPLASMS^10^169
 +87      ;;^UTILITY(U,$J,358.4,1860,0)
 +88      ;;=METASTATIC SITES^11^169
 +89      ;;^UTILITY(U,$J,358.4,1861,0)
 +90      ;;=MALIGNANT NEOPLASMS OF OTHER SITES^12^169
 +91      ;;^UTILITY(U,$J,358.4,1862,0)
 +92      ;;=MYELOID NEOPLASMS AND DISORDERS^13^169
 +93      ;;^UTILITY(U,$J,358.4,1863,0)
 +94      ;;=NEOPLASM OF UNCERTAIN BEHAVIOR^14^169
 +95      ;;^UTILITY(U,$J,358.4,1864,0)
 +96      ;;=NEOPLASM OF UNSPECIFIED NATURE^15^169
 +97      ;;^UTILITY(U,$J,358.4,1865,0)
 +98      ;;=PERSONAL HISTORY^16^169
 +99      ;;^UTILITY(U,$J,358.4,1866,0)
 +100     ;;=INJECTION/ASPIRATION^3^170
 +101     ;;^UTILITY(U,$J,358.4,1867,0)
 +102     ;;=FRACTURE DISLOCATION^2^170
 +103     ;;^UTILITY(U,$J,358.4,1868,0)
 +104     ;;=APPLICATION CASTS/STRAPPING^1^170
 +105     ;;^UTILITY(U,$J,358.4,1869,0)
 +106     ;;=OTHER/REMOVAL/REVISION^4^170
 +107     ;;^UTILITY(U,$J,358.4,1870,0)
 +108     ;;=SUPPLIES/SOFT GOODS^7^170
 +109     ;;^UTILITY(U,$J,358.4,1871,0)
 +110     ;;=SUPPLIES/DRUGS^6^170
 +111     ;;^UTILITY(U,$J,358.4,1872,0)
 +112     ;;=REPAIR/CLOSURE-SIMPLE^5^170
 +113     ;;^UTILITY(U,$J,358.4,1873,0)
 +114     ;;=NEW PATIENT^2^171
 +115     ;;^UTILITY(U,$J,358.4,1874,0)
 +116     ;;=ESTABLISHED PATIENT^1^171